Strategies for enhanced photodynamic therapy effects

Photochemistry and Photobiology

Volumn 83, Issue 5, 2007, Pages 996-1005

  Verma, Sarika ^a   Watt, Gregory M ^a   Mai, Zhiming ^a   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT;

CONFERENCE PAPER; DRUG COMBINATION; PHOTOCHEMOTHERAPY;

DRUG THERAPY, COMBINATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 34548705462     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-1097.2007.00166.x     Document Type: Conference Paper

References (111)

1. Raab, O. (1900) Über die wirkung Fluoreszierender Stoffe auf Infusoria (Action of fluorescent materials on infusorial substances). Z. Biol. 39, 524 546.
2. Hamblin, M. R. T. Hasan (1996) Advances in photodynamic theory [therapy]. Optics Photonics News 7, 16 21.
3. Dougherty, T. J. (2002) An update on photodynamic therapy applications. J. Clin. Laser Med. Surg. 20, 3 7.
4. Garcia-Zuazaga, J., K. D. Cooper E. D. Baron (2005) Photodynamic therapy in dermatology: Current concepts in the treatment of skin cancer. Expert Rev. Anticancer Ther. 5, 791 800.
5. Henderson, B. W., T. M. Busch J. W. Snyder (2006) Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med. 38, 489 493.
6. Foster, T. H., D. F. Hartley, M. G. Nichols R. Hilf (1993) Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res. 53, 1249 1254.
7. Chen, Q., Z. Huang, H. Chen, H. Shapiro, J. Beckers F. W. Hetzel (2002) Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem. Photobiol. 76, 197 203.
8. Foster, T. H., R. S. Murant, R. G. Bryant, R. S. Knox, S. L. Gibson R. Hilf (1991) Oxygen consumption and diffusion effects in photodynamic therapy. Radiat. Res. 126, 296 303.
9. Henderson, B. W. T. J. Dougherty (1992) How does photodynamic therapy work? Photochem. Photobiol. 55, 145 157.
10. Detty, M. R., S. L. Gibson S. J. Wagner (2004) Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 47, 3897 3915.
11. Sharman, W. M., C. M. Allen J. E. van Lier (1999) Photodynamic therapeutics: Basic principles and clinical applications. Drug Discov. Today 4, 507 517.
12. Dougherty, T. J. (1984) Photodynamic therapy (PDT) of malignant tumors. Crit. Rev. Oncol. Hematol. 2, 83 116.
13. Tsukagoshi, S. (1995) Porfimer sodium (Photofrin -II). Gan to kagaku ryoho. Cancer Chemother. 22, 1271 1278.
14. Moriwaki, S. I., J. Misawa, Y. Yoshinari, I. Yamada, M. Takigawa Y. Tokura (2001) Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin). Photodermatol. Photoimmunol. Photomed. 17, 241 243.
15. Azab, M., D. S. Boyer, N. M. Bressler, S. B. Bressler, I. Cihelkova, Y. Hao, I. Immonen, J. I. Lim, U. Menchini, J. Naor, M. J. Potter, A. Reaves, P. J. Rosenfeld, J. S. Slakter, P. Soucek, H. A. Strong, A. Wenkstern, X. Y. Su Y. C. Yang (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch. Ophthalmol. 123, 448 457.
16. Gomer, C. J., A. Ferrario, M. Luna, N. Rucker S. Wong (2006) Photodynamic therapy: Combined modality approaches targeting the tumor microenvironment. Lasers Surg. Med. 38, 516 521.
17. Sitnik, T. M., J. A. Hampton B. W. Henderson (1998) Reduction of tumour oxygenation during and after photodynamic therapy in vivo: Effects of fluence rate. Br. J. Cancer 77, 1386 1394.
18. Henderson, B. W., T. M. Busch, L. A. Vaughan, N. P. Frawley, D. Babich, T. A. Sosa, J. D. Zollo, A. S. Dee, M. T. Cooper, D. A. Bellnier, W. R. Greco A. R. Oseroff (2000) Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res. 60, 525 529.
19. Engbrecht, B. W., C. Menon, A. V. Kachur, S. M. Hahn D. L. Fraker (1999) Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res. 59, 4334 4342.
20. Fingar, V. H., P. K. Kik, P. S. Haydon, P. B. Cerrito, M. Tseng, E. Abang T. J. Wieman (1999) Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer 79, 1702 1708.
21. Forsythe, J. A., B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos G. L. Semenza (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 4604 4613.
22. Solban, N., P. K. Selbo, A. K. Sinha, S. K. Chang T. Hasan (2006) Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res. 66, 5633 5640.
23. Ferrario, A., K. F. von Tiehl, N. Rucker, M. A. Schwarz, P. S. Gill C. J. Gomer (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 60, 4066 4069.
24. Ferrario, A., K. Von Tiehl, S. Wong, M. Luna C. J. Gomer (2002) Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 62, 3956 3961.
25. Ferrario, A., C. F. Chantrain, K. von Tiehl, S. Buckley, N. Rucker, D. R. Shalinsky, H. Shimada, Y. A. DeClerck C. J. Gomer (2004) The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 64, 2328 2332.
26. Kosharskyy, B., N. Solban, S. K. Chang, I. Rizvi, Y. Chang T. Hasan (2006) A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res. 66, 10953 10958.
27. Ortel, B., D. Sharlin, D. O'Donnell, A. K. Sinha, E. V. Maytin T. Hasan (2002) Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br. J. Cancer 87, 1321 1327.
28. Marks, P. A. R. A. Rifkind (1991) Differentiating agents in cancer therapy. Cancer Chemother. Biol. Response Modif. 12, 291 305.
29. Sinha, A. K., S. Anand, B. J. Ortel, Y. Chang, Z. Mai, T. Hasan E. V. Maytin (2006) Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br. J. Cancer 95, 485 495.
30. Funovics, M., R. Weissleder C. H. Tung (2003) Protease sensors for bioimaging. Anal. Bioanal. Chem. 377, 956 963.
31. Pham, W., Y. Choi, R. Weissleder C. H. Tung (2004) Developing a peptide-based near-infrared molecular probe for protease sensing. Bioconjug.Chem. 15, 1403 1407.
32. Neefjes, J. N. P. Dantuma (2004) Fluorescent probes for proteolysis: Tools for drug discovery. Nat. Rev. Drug Discov. 3, 58 69.
33. Law, B., R. Weissleder C. H. Tung (2006) Peptide-based biomaterials for protease-enhanced drug delivery. Biomacromolecules 7, 1261 1265.
34. Xing, B., A. Khanamiryan J. Rao (2005) Cell-permeable near-infrared fluorogenic substrates for imaging beta-lactamase activity. J. Am. Chem. Soc. 127, 4158 4159.
35. Deonarain, M. P. A. A. Epenetos (1994) Targeting enzymes for cancer therapy: Old enzymes in new roles. Br. J. Cancer 70, 786 794.
36. Niculescu-Duvaz, I. C. J. Springer (1997) Antibody-directed enzyme prodrug therapy (ADEPT): A review. Adv. Drug. Deliv. Rev. 26, 151 172.
37. Krinick, N. L., Y. Sun, D. Joyner, J. D. Spikes, R. C. Straight J. Kopecek (1994) A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed. 5, 303 324.
38. Konan, Y. N., R. Gurny E. Allémann (2002) State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B, Biol. 66, 89 106.
39. Solban, N., I. Rizvi T. Hasan (2006) Targeted photodynamic therapy. Lasers Surg. Med. 38, 522 531.
40. Barrett, A. J., J. C. Kennedy, R. A. Jones, P. Nadeau R. H. Pottier (1990) The effect of tissue and cellular pH on the selective biodistribution of porphyrin-type photochemotherapeutic agents: A volumetric titration study. J. Photochem. Photobiol. B 6, 309 323.
41. Dougherty, T. J., C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan Q. Peng (1998) Photodynamic therapy. J. Natl. Cancer Inst. 90, 889 905.
42. Zhou, X., P. W. Pogue, B. Chen T. Hasan (2004) Analysis of effective molecular diffusion rates for verteporfin in subcutaneous versus orthotopic Dunning prostate tumors. Photochem. Photobiol. 79, 323 331.
43. Stewart, F., P. Baas W. Star (1998) What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? Radiother. Oncol. 48, 233 248.
44. Chen, B., T. Roskams, Y. Xu, P. Agostinis P. A. de Witte (2002) Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int. J. Cancer 98, 284 290.
45. Veenhuizen, R., H. Oppelaar, M. Ruevekamp, J. Schellens, O. Dalesio F. Stewart (1997) Does tumour uptake of Foscan determine PDT efficacy? Int. J. Cancer 73, 236 239.
46. Chen, B., Y. Xu, T. Roskams, E. Delaey, P. Agostinis, J. R. Vandenheede P. de Witte (2001) Efficacy of antitumoral photodynamic therapy with hypericin: Relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int. J. Cancer 93, 275 282.
47. Dolmans, D. E., A. Kadambi, J. S. Hill, C. A. Waters, B. C. Robinson, J. P. Walker, D. Fukumura R. K. Jain (2002) Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res. 62, 2151 2156.
48. Cramers, P., M. Ruevekamp, H. Oppelaar, O. Dalesio, P. Baas F. A. Stewart (2003) Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br. J. Cancer 88, 283 290.
49. Fingar, V. H. (1996) Vascular effects of photodynamic therapy. J. Clin. Laser Med. Surg. 14, 323 328.
50. 2 dynamics during photodynamic therapy with verteporfin. Photochem. Photobiol. 74, 700 706.
51. Brown, S. B. K. J. Mellish (2001) Verteporfin: A milestone in opthalmology and photodynamic therapy. Expert Opin. Pharmacother. 2, 351 361.
52. Koudinova, N. V., J. H. Pinthus, A. Brandis, O. Brenner, P. Bendel, J. Ramon, Z. Eshhar, A. Scherz Y. Salomon (2003) Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): Successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int. J. Cancer 104, 782 789.
53. Schreiber, S., S. Gross, A. Brandis, A. Harmelin, V. Rosenbach-Belkin, A. Scherz Y. Salomon (2002) Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increase of animal cure compared with surgery. Int. J. Cancer 99, 279 285.
54. Chen, B., B. W. Pogue, P. J. Hoopes T. Hasan (2005) Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int. J. Radiat. Oncol. Biol. Phys. 61, 1216 1226.
55. Veenhuizen, R. B., M. C. Ruevekamp, H. Oppelaar, T. J. Helmerhorst, P. Kenemans F. A. Stewart (1997) Foscan-mediated photodynamic therapy for a peritoneal-cancer model: Drug distribution and efficacy studies. Int. J. Cancer 73, 230 235.
56. Triesscheijn, M., M. Ruevekamp, M. Aalders, P. Baas F. A. Stewart (2005) Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response. Photochem. Photobiol. 81, 1161 1167.
57. Reddi, E. (1997) Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. J. Photochem. Photobiol. B, Biol. 37, 189 195.
58. Polo, L., G. Valduga, G. Jori E. Reddi (2002) Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int. J. Biochem. Cell Biol. 34, 10 23.
59. Chen, B., B. W. Pogue T. Hasan (2005) Liposomal delivery of photosensitizing agents. Expert Opin. Drug Deliv. 2, 477 487.
60. Vrouenraets, M. B., G. W. Visser, C. Loup, B. Meunier, M. Stigter, H. Oppelaar, F. A. Stewart, G. B. Snow G. A. van Dongen (2000) Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy. Int. J. Cancer 88, 108 114.
61. Shadidi, M. M. Sioud (2003) Selective targeting of cancer cells using synthetic peptides. Drug. Resist. Updat. 6, 363 371.
62. Sharman, W. M., J. E. van Lier C. M. Allen (2004) Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug Deliv. Rev. 56, 53 76.
63. Hamblin, M. R., J. L. Miller B. Ortel (2000) Scavenger-receptor targeted photodynamic therapy. Photochem. Photobiol. 72, 533 540.
64. Hamblin, M. R. E. L. Newman (1994) Photosensitizer targeting in photodynamic therapy. I. Conjugates of haematoporphyrin with albumin and transferring. J. Photochem. Photobiol. B, Biol. 26, 45 56.
65. Van Nostrum, C. F. (2004) Delivery of photosensitizers in photodynamic therapy. Adv. Drug Deliv. Rev. 56, 5 6.
66. Allison, B. A., P. H. Pritchard J. G. Levy (1994) Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br. J. Cancer 69, 833 839.
67. Misawa, J., S. Moriwaki, E. Kohno, T. Hirano, Y. Tokura M. Takigawa (2005) The role of low-density lipoprotein receptors in sensitivity to killing by Photofrin-mediated photodynamic therapy in cultured human tumor cell lines. J. Dermatol. Sci. 40, 59 61.
68. Aquaron, R., J.-L. Murati, G. Fayet, C. Aquaron B. Ridings (2002) Simple, reliable and fast spectrofluorometric method for determination of plasma verteporfin (Visudyne) levels during photodynamic therapy for choroidal neovascularization. Cell. Mol. Biol. 48, 925 930.
69. Kessel, D., L. K. Whitcomb V. Schulz (1992) Lipoprotein-mediated distribution of N-aspartylchlorin e6 in the mouse. Photochem. Photobiol. 56, 51 56.
70. Schmidt-Erfurth, U., H. Diddens, R. Birngruber T. Hasan (1997) Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br. J. Cancer 75, 54 61.
71. Soukos, N. S., M. R. Hamblin, S. Keel, R. L. Fabian, T. F. Deutsch T. Hasan (2001) Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res. 61, 4490 4496.
72. Savellano, M. D. T. Hasan (2003) Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol. 77, 431 439.
73. Duska, L. R., M. R. Hamblin, M. P. Bamberg T. Hasan (1997) Biodistribution of charged F(ab′)2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer 75, 837 844.
74. Merdan, T., J. Callahan, H. Petersen, K. Kunath, U. Bakowsky, P. Kopeckova, T. Kissel J. Kopecek (2003) Pegylated polyethylenimine-Fab′ antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjug. Chem. 14, 989 996.
75. Savellano, M. D. T. Hasan (2005) Photochemical targeting of epidermal growth factor receptor: A mechanistic study. Clin. Cancer Res. 11, 1658 1668.
76. Van Dongen, G. A., G. W. Visser M. B. Vrouenraets (2004) Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv. Drug Deliv. Rev. 56, 31 52.
77. Kessel, D. (2004) Correlation between subcellular localization and photodynamic efficacy. J. Porphyrins Phthalocyanines 8, 1009 1014.
78. Schneider, R., L. Tirand, C. Frochot, R. Vanderesse, N. Thomas, J. Gravier, F. Guillemin M. Barberi-Heyob (2006) Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. Anticancer Agents Med. Chem. 6, 469 488.
79. Rahimipour, S., N. Ben-Aroya, K. Ziv, A. Chen, M. Fridkin Y. Koch (2003) Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J. Med. Chem. 46, 3965 3974.
80. Ichikawa, K., T. Hikita, N. Maeda, S. Yonezawa, Y. Takeuchi, T. Asai, Y. Namba N. Oku (2005) Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim. Biophys. Acta 1669, 69 74.
81. Renno, R. Z., Y. Terada, M. J. Haddadin, N. A. Michaud, E. S. Gragoudas J. W. Miller (2004) Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch. Ophthalmol. 122, 1002 1011.
82. Binetruy-Tournaire, R., C. Demangel, B. Malavaud, R. Vassy, S. Rouyre, M. Kraemer, J. Plouet, C. Derbin, G. Perret J. C. Mazie (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 19, 1525 1533.
83. Tirand, L., C. Frochot, R. Vanderesse, N. Thomas, E. Trinquet, S. Pinel, M. L. Viriot, F. Guillemin M. A. Barberi-Heyob (2006) A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J. Control. Release 111, 153 164.
84. Jans, D. A., C. Y. Xiao M. H. Lam (2000) Nuclear targeting signal recognition: A key control point in nuclear transport? Bioessays 22, 532 544.
85. Sobolev, A. S., D. A. Jans A. A. Rosenkranz (2000) Targeted intracellular delivery of photosensitizers. Prog. Biophys. Mol. Biol. 73, 51 90.
86. Dozzo, P., M. S. Koo, S. Berger, T. M. Forte S. B. Kahl (2005) Synthesis, characterization, and plasma lipoprotein association of a nucleus-targeted boronated porphyrin. J. Med. Chem. 48, 357 359.
87. Sibrian-Vazquez, M., E. Hao, T. J. Jensen M. G. Vicente (2006) Enhanced cellular uptake with a cobaltacarborane-porphyrin-HIV-1 Tat 48-60 conjugate. Bioconjug. Chem. 17, 928 934.
88. Newton, J. R., K. A. Kelly, U. Mahmood, R. Weissleder S. L. Deutscher (2006) In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 8, 772 780.
89. Hasan, T. (1992) Photosensitizer delivery mediated by macromolecular carrier systems. In Photodynamic Therapy: Basic Principles and Clinical Applications (Edited by B. Henderson T. Dougherty pp. 187 200. Marcel Dekker, New York.
90. Roby, A., S. Erdogan V. P. Torchilin (2006) Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur. J. Pharm. Biopharm. 62, 235 240.
91. Hamblin, M. R., J. L. Miller, I. Rizvi, B. Ortel, E. V. Maytin T. Hasan (2001) Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res. 61, 7155 7162.
92. Sadzuka, Y., K. Tokutomi, F. Iwasaki, I. Sugiyama, T. Hirano, H. Konno, N. Oku T. Sonobe (2006) The phototoxicity of photofrin was enhanced by PEGylated liposome in vitro. Cancer Lett. 241, 42 48.
93. Tijerina, M., P. Kopeckova J. Kopecek (2003) Mechanisms of cytotoxicity in human ovarian carcinoma cells exposed to free Mce6 or HPMA copolymer-Mce6 conjugates. Photochem. Photobiol. 77, 645 652.
94. Wang, S., R. Gao, F. Zhou M. Selke (2004) Nanomaterials and singlet oxygen photosensitizers: Potential applications in photodynamic therapy. J. Mater. Chem. 14, 487 493.
95. Gomes, A. J., A. S. Faustino, A. E. H. Machado, M. E. D. Zaniquelli, T. P. Rigoletto, C. N. Lunardi L. O. Lunardi (2006) Characterization of PLGA microparticles as a drug carrier for 3-ethoxycarbonyl-2h-benzofuro[3,2-f]-1- benzopyran-2-one. Ultrastructural study of cellular uptake and intracellular distribution. Drug Deliv. 13, 447 454.
96. Konan, Y., J. Chevallier, R. Gurny E. Allemann (2003) Encapsulation of p-THPP into nanoparticles: Cellular uptake, subcellular localization and effect of serum on photodynamic activity. Photochem. Photobiol. 77, 638 644.
97. Ricci-Júnior, E. J. M. Marchetti (2006) Preparation, characterization, photocytotoxicity assay of PLGA nanoparticles containing zinc (II) phthalocyanine for photodynamic therapy use. J. Microencapsul. 23, 523 538.
98. Pegaz, B., E. Debefve, F. Borle, J.-P. Ballini, H. van den Bergh Y. N. Kouakou-Konan (2005) Encapsulation of porphyrins and chlorins in biodegradable nanoparticles: The effect of dye lipophilicity on the extravasation and the photothrombic activity. A comparative study. J. Photochem. Photobiol. B, Biol. 80, 19 27.
99. McCarthy, J. R., J. M. Perez, C. Bruckner R. Weissleder (2005) Polymeric nanoparticle preparation that eradicates tumors. Nano Lett. 5, 2552 2556.
100. Zeisser-Labouebe, M., N. Lange, R. Gurny F. Delie (2006) Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int. J. Pharm. 326, 174 181.
101. Weiner, L. M. G. P. Adams (2000) New approaches to antibody therapy. Oncogene 19, 6144 6151.
102. Ellington, A. D. J. W. Szostak (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818 822.
103. Brody, E. N. L. Gold (2000) Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74, 5 13.
104. Moshfeghi, A. A. C. A. Puliafito (2006) Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin. Investig. Drugs 14, 671 682.
105. Cerchia, L. V. de Franciscis (2006) Nucleic acid-based aptamers as promising therapeutics in neoplastic diseases. Methods Mol. Biol. 361, 187 200.
106. Ireson, C. R. L. R. Kelland (2006) Discovery and development of anticancer aptamers. Mol. Cancer Ther. 5, 2957 2962.
107. Senior, K. (2006) Aptamers as potential probes for cancer. Lancet Oncol. 7, 712 712.
108. Farokhzad, O. C., J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie R. Langer (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103, 6315 6320.
109. Thodima, V., M. Pirooznia Y. Deng (2006) RiboaptDB: A comprehensive database of ribozymes and aptamers. BMC Bioinformatics, 7 (Suppl. 2 S6.
110. Burmeister, P. E., S. D. Lewis, R. F. Silva, J. R. Preiss, L. R. Horwitz, P. S. Pendergrast, T. G. McCauley, J. C. Kurz, D. M. Epstein, C. Wilson A. D. Keefe (2005) Direct in vitro selection of a 2′-o-methyl aptamer to VEGF. Chem. Biol. 12, 25 33.
111. Reddy, G. R., M. S. Bhojani, P. McConville, J. Moody, B. A. Moffat, D. E. Hall, G. Kim, Y. E. Koo, M. J. Woolliscroft, J. V. Sugai, T. D. Johnson, M. A. Philbert, R. Kopelman, A. Rehemtulla B. D. Ross (2006) Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res. 12, 6677 6686.